The relationship between HIV infection and cardiovascular disease

Current Cardiology Reviews

Volumn 4, Issue 3, 2008, Pages 203-218

  Dau, Birgitt ^a   Holodniy, Mark ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Cardiology; HIV; Natural history; Review; Treatment

Indexed keywords

EID: 54749114475     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340308785160589     Document Type: Review

References (170)

1. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992 Dec 18; 41(RR-17): 1-19.
2. UNAIDS Joint United Nation Programme on HIV/AIDS.
3. HIV/AIDS Statistics and Surveillance. Centers for Disease Control.
4. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://www.idsinfo.nih.gov/guidelines. Accessed March 15th, 2008 2008.
5. Mondy K, Tebas P. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis 2003; 36(Suppl 2): S101-5.
6. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74(5): 1045-52.
7. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993; 76(6): 1423-7.
8. White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect 2001; 77(3): 158-73.
9. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003 1; 37(5): 613-27.
10. Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003; 42(2): 81-92.
11. Authier FJ, Chariot P, Gherardi RK. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve 2005; 32(3): 247-60.
12. Thomas CM, Smart EJ. How HIV protease inhibitors promote atherosclerotic lesion formation. Curr Opin Lipidol 2007; 18(5): 561-5.
13. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351(9119): 1881-3.
14. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000; 2: S135-42.
15. Moyle G. Metabolic issues associated with protease inhibitors. J Acquir Immune Defic Syndr 2007; 45(Suppl 1): S19-26.
16. Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21(18): 2445-53.
17. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007; 30(1): 113-9.
18. Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45(1): 111-9.
19. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D: A: D study. Diabetes Care 2008; 31(6): 1224-9.
20. Salehian B, Bilas J, Bazargan M, Abbasian M. Prevalence and incidence of diabetes in HIV-infected minority patients on protease inhibitors. J Natl Med Assoc 2005; 97(8): 1088-92.
21. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275(27): 20251-4.
22. Nolte LA, Yarasheski KE, Kawanaka K, Fisher J, Le N, Holloszy JO. The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. Diabetes 2001; 50(6): 1397-401.
23. Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18(16): 2137-44.
24. Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20(14): 1813-21.
25. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19(13): 1375-83.
26. Fleischman A, Johnsen S, Systrom DM, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2007; 292(6): E1666-73.
27. Chuck SK, Penzak SR. Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia. Expert Opin Drug Saf 2002; 1(1): 5-17.
28. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://www.aidsinfo.nih.gov/guidelines. Accessed March 15th, 2008.
29. Liverpool HIV Pharmacology Group. HIV Drug Interactions.
30. Gianotti N, Guffanti M, Galli L, et al. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. AIDS 2007; 21(12): 1648-51.
31. Telenti A, Zanger UM. Pharmacogenetics of anti-HIV drugs. Annual review of pharmacology and toxicology 2008; 48: 227-56.
32. Arnedo M, Taffe P, Sahli R, et al. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genomics 2007; 17(9): 755-64.
33. Hsue PY, Lo JC, Franklin A, Bolger AF, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109(13): 1603-8.
34. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185(4): 456-62.
35. van Leuven SI, Franssen R, Kastelein JJ, Levi M, Stroes ES, Tak PP. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford) 2008; 47(1): 3-7.
36. Torre D. Nitric oxide and endothelial dysfunction in HIV type 1 infection. Clin Infect Dis 2006; 43(8): 1086-7.
37. Paladugu R, Fu W, Conklin BS, et al. Hiv Tat protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg 2003; 38(3): 549-55.
38. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G. The effects of HIV infection on endothelial function. Endothelium 2000; 7(4): 223-42.
39. Mu H, Chai H, Lin PH, Yao Q, Chen C. Current update on HIV-associated vascular disease and endothelial dysfunction. World J Surg 2007; 31(4): 632-43.
40. Currie PF, Boon NA. Immunopathogenesis of HIV-related heart muscle disease: current perspectives. AIDS 2003; 17(Suppl 1): S21-8.
41. de Larranaga GF, Petroni A, Deluchi G, Alonso BS, Benetucci JA. Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagul Fibrinolysis 2003; 14(1): 15-8.
42. Dhawan S, Puri RK, Kumar A, Duplan H, Masson JM, Aggarwal BB. Human immunodeficiency virus-1-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. Blood 1997; 90(4): 1535-44.
43. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86(1): 27-31.
44. El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviralnaive cohort. HIV Med 2005; 6(2): 114-21.
45. Aukrust P, Bjornsen S, Lunden B, et al. Persistently elevated levels of von Willebrand factor antigen in HIV infection. Downregulation during highly active antiretroviral therapy. Thromb Haemost 2000; 84(2): 183-7.
46. Schecter AD, Berman AB, Yi L, et al. HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci USA 2001; 98(18): 10142-7.
47. Hsue PY, Waters DD. What a cardiologist needs to know about patients with human immunodeficiency virus infection. Circulation 2005; 112(25): 3947-57.
48. Solages A, Vita JA, Thornton DJ, et al. Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42(9): 1325-32.
49. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104(3): 257-62.
50. Jiang B, Hebert VY, Zavecz JH, Dugas TR. Antiretrovirals induce direct endothelial dysfunction in vivo. J Acquir Immune Defic Syndr 2006; 42(4): 391-5.
51. de Gaetano Donati K, Rabagliati R, Iacoviello L, Cauda R. HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect Dis 2004; 4(4): 213-22.
52. Passalaris JD, Sepkowitz KA, Glesby MJ. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 2000; 31(3): 787-97.
53. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92(7): 2506-12.
54. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44(12): 1625-31.
55. Klein D, Hurley LB, Quesenberry CP, Jr., Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30(5): 471-7.
56. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360(9347): 1747-8.
57. Barbaro G, Di Lorenzo G, Cirelli A, et al. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther 2003; 25(9): 2405-18.
58. Iloeje UH, Yuan Y, L'Italien G, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6(1): 37-44.
59. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17(17): 2479-86.
60. Kwong GP, Ghani AC, Rode RA, et al. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. AIDS 2006; 20(15): 1941-50.
61. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17(8): 1179-93.
62. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356(17): 1723-35.
63. Stein JH. Cardiovascular risks of antiretroviral therapy. N Engl J Med 2007; 356(17): 1773-5.
64. Sabin C, Worm S, Weber, R. Do thymidine analogues abacavir, didanosine and lamivudine contribute to the risk of myocardial infarction? The D: A: D study. Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections Abstract 957c 2008 Feb.
65. Kaplan RC, Tien PC, Lazar J. Antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 357(7): 715; author reply 6-7.
66. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006 355(22): 2283-96.
67. Kuller L. Elevated levles of interluekin-6 and D-dimer are associated with an increased risk of death in patients with HIV. Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections Abstract 139 2008 Feb.
68. Calmy A, Nguyen A, Montecucco, F. HIV activates markers of cardiovascular risk in a randomized treatment interruption trial: STACCATO. Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections Abstract 140 2008 Feb.
69. Papasavvas E, Azzoni, L., Pistilli, M. Acute viral rebound as a result of structured treatment interruptions in chronically HIV-1-infected subjects: A pathway to cardiovascular risk? Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections Abstract 964 2008 Feb.
70. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348(8): 702-10.
71. Mercie P, Thiebaut R, Aurillac-Lavignolle V, et al. Carotid intimamedia thickness is slightly increased over time in HIV-1-infected patients. HIV Med 2005; 6(6): 380-7.
72. Jerico C, Knobel H, Calvo N, et al. Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy. Stroke 2006; 37(3): 812-7.
73. Maggi P, Serio G, Epifani G, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000; 14(16): F123-8.
74. Coll B, Parra S, Alonso-Villaverde C, et al. The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection. Stroke 2007; 38(9): 2477-84.
75. Alonso-Villaverde C, Coll B, Parra S, et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 2004; 110(15): 2204-9.
76. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intimamedia thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20(18): 2275-83.
77. McComsey GA, O'Riordan M, Hazen SL, El-Bejjani D, et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS 2007; 21(8): 921-7.
78. Currier JS, Kendall MA, Henry WK, et al. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 2007; 21(9): 1137-45.
79. Currier JS, Kendall MA, Zackin R, et al. Carotid artery intimamedia thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005; 19(9): 927-33.
80. Coll B, Alonso-Villaverde C, Masana L. Carotid intima-media thickness course in HIV-infected patients: beyond classical cardiovascular risk factors. AIDS 2007; 21(14): 1989-90.
81. Herskowitz A, Vlahov D, Willoughby S, et al. Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection. Am J Cardiol 1993; 71(11): 955-8.
82. Herskowitz A, Wu TC, Willoughby SB, et al. Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. J Am Coll Cardiol 1994; 24(4): 1025-32.
83. Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000; 40(3): 282-4.
84. Mayosi BM. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart 2007; 93(10): 1176-83.
85. Sudano I, Spieker LE, Noll G, Corti R, Weber R, Luscher TF. Cardiovascular disease in HIV infection. Am Heart J 2006; 151(6): 1147-55.
86. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G. Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. AIDS Res Hum Retroviruses 1998; 14(12): 1071-7.
87. Heidenreich PA, Eisenberg MJ, Kee LL, Somelofski CA, Hollander H, Schiller NB, et al. Pericardial effusion in AIDS. Incidence and survival. Circulation 1995; 92(11): 3229-34.
88. Louw A, Tikly M. Purulent pericarditis due to co-infection with Streptococcus pneumoniae and Mycobacterium tuberculosis in a patient with features of advanced HIV infection. BMC Infect Dis 2007; 7: 12.
89. Jinno S, Jirakulaporn T, Bankowski MJ, Kim W, Wong R. Rare case of Nocardia asteroides pericarditis in a human immunodeficiency virus-infected patient. J Clin Microbiol 2007; 45(7): 2330-3.
90. Ramanathan P, Rahimi AR. Nocardia asteroides pericarditis in association with HIV. AIDS Patient Care STDS 2000; 14(12): 621-5.
91. Rapose A, Sarvat B, Sarria JC. Immune reconstitution inflammatory syndrome presenting as pericarditis and pericardial effusion. Cardiology 2007; 17; 110(2): 142-4.
92. Mayosi BM, Wiysonge CS, Ntsekhe M, et al. Clinical characteristics and initial management of patients with tuberculous pericarditis in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI Africa) registry. BMC Infect Dis 2006; 6: 2.
93. Ntsekhe M, Hakim J. Impact of human immunodeficiency virus infection on cardiovascular disease in Africa. Circulation 2005; 112(23): 3602-7.
94. Saber AA, Aboolian A, LaRaja RD, Baron H, Hanna K. HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement. Am Surg 2001; 67(7): 645-7.
95. Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 2001; 15(6): 311-20.
96. Fultz SL, McGinnis KA, Skanderson M, Ragni MV, Justice AC. Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. Am J Med 2004; 116(6): 420-3.
97. Lijfering WM, Sprenger HG, Georg RR, van der Meulen PA, van der Meer J. Relationship between progression to AIDS and thrombophilic abnormalities in HIV infection. Clin Chem 2008; [Epub ahead of print].
98. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991; 100(5): 1268-71.
99. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008; 177(1): 108-13.
100. Barnett CF, Hsue PY, Machado RF. Pulmonary hypertension: an increasingly recognized complication of hereditary hemolytic anemias and HIV infection. JAMA 2008; 299(3): 324-31.
101. Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004; 38(8): 1178-85.
102. Taichman DB, Mandel J. Epidemiology of pulmonary arterial hypertension. Clin Chest Med 2007; 28(1): 1-22, vii.
103. Barbarinia G, Barbaro G. Incidence of the involvement of the cardiovascular system in HIV infection. AIDS 2003; 17(Suppl 1): S46-50.
104. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18): 1837-47.
105. Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 2007; 45(8): 1074-81.
106. Lloyd-Jones DM, Wilson PW, Larson MG, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004; 94(1): 20-4.
107. Law MG, Friis-Moller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIVinfected patients: comparison with observed events in the D: A: D Study. HIV Med 2006; 7(4): 218-30.
108. Dressman J, Kincer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 2003; 111(3): 389-97.
109. Friis-Moller N, Worm SW. Can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools? Clin Infect Dis 2007; 45(8): 1082-4.
110. Stein JH. Managing cardiovascular risk in patients with HIV infection. J Acquir Immune Defic Syndr 2005; 38(2): 115-23.
111. Friis-Moller N TR, Reiss P, et al. Predicting the risk of coronary heart disease in HIV-infected patients: the D: A: D risk equation. Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections 2007; Los Angeles, California.Abstract 808.
112. Maggi P, Lillo A, Perilli F, Maserati R, Chirianni A. Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS 2004; 18(7): 1023-8.
113. Guimaraes MM, Greco DB, Figueiredo SM, Foscolo RB, Oliveira AR, Jr., Machado LJ. High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection. Atherosclerosis 2008 Feb 15.
114. Feldman JG, Goldwasser P, Holman S, DeHovitz J, Minkoff H. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr 2003; 32(2): 210-4.
115. Masia M, Bernal E, Padilla S, et al. The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Atherosclerosis 2007; 195(1): 167-71.
116. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352(1): 48-62.
117. De Socio GV, Martinelli L, Morosi S, et al. Is estimated cardiovascular risk higher in HIV-infected patients than in the general population? Scand J Infect Dis 2007; 39(9): 805-12.
118. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349(21): 1993-2003.
119. De Socio GV, Parruti G, Quirino T, et al. Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: Results from the SIMONE study. J Infect 2008; [Epub ahead of print].
120. Glass TR, Ungsedhapand C, Wolbers M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med 2006; 7(6): 404-10.
121. Elzi L, Spoerl D, Voggensperger J, et al. A smoking cessation programme in HIV-infected individuals: a pilot study. Antivir Ther 2006; 11(6): 787-95.
122. Vidrine DJ, Arduino RC, Lazev AB, Gritz ER. A randomized trial of a proactive cellular telephone intervention for smokers living with HIV/ AIDS. AIDS 2006; 20(2): 253-60.
123. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165(10): 1179-84.
124. Mondy K, Overton ET, Grubb J, et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007; 44(5): 726-34.
125. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142(8): 611-9.
126. Standards of medical care in diabetes - 2008. Diabetes Care 2008 Jan; 31(Suppl 1): S12-54.
127. Bury JE, Stroup JS, Stephens JR, Baker DL. Achieving American Diabetes Association goals in HIV-seropositive patients with diabetes mellitus. Proc (Bayl Univ Med Cent) 2007; 20(2): 118-23.
128. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. american heart association science advisory and coordinating committee. Circulation 2002; 106(3): 388-91.
129. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560-72.
130. Fitch KV, Anderson EJ, Hubbard JL, et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS 2006; 20(14): 1843-50.
131. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998; 352(9133): 1031-2.
132. Jones SP, Doran DA, Leatt PB, Maher B, Pirmohamed M. Shortterm exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. AIDS 2001; 15(15): 2049-51.
133. Wohl DA, Tien HC, Busby M, et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis 2005; 41(10): 1498-504.
134. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227-39.
135. Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005; 19(10): 1051-8.
136. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007; 44(11): 1484-92.
137. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002; 35(10): 1219-30.
138. Busti AJ, Bedimo R, Margolis DM, Hardin DS. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. J Investig Med 2008; 56(2): 539-44.
139. Sekar VJ S-GS, Marien K. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin 8th International Workshop on Pharmacology of HIV Therapy, Budapest 2007 August 16-18; Abstract 55.
140. Calza L, Colangeli V, Manfredi R, et al. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 2005; 19(10): 1103-5.
141. Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug/ Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers. J Acquir Immune Defic Syndr 2008; 47(5): 570-8.
142. Aboulafia DM, Johnston R. Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. AIDS Patient Care STDS 2000; 14(1): 13-8.
143. Castro JG, Gutierrez L. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. Am J Med 2002; 112(6): 505.
144. Cheng CH, Miller C, Lowe C, Pearson VE. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm 2002; 59(8): 728-30.
145. Hare CB, Vu MP, Grunfeld C, Lampiris HW. Simvastatinnelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis 2002; 35(10): e111-2.
146. Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDS 2003; 17(5): 207-10.
147. Mastroianni CM, d'Ettorre G, Forcina G, et al. Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. AIDS 2001; 15(6): 820-1.
148. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services 2008: 1-128.
149. Gatell. SWAN: Final 48-week Lipid Results of Switch to ATV 10th European AIDS Conference 2005; Abstract#PS1/1.
150. Visnegarwala F, Maldonado M, Sajja P, et al. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J Infect 2004; 49(4): 283-90.
151. Aberg JA, Zackin RA, Brobst SW, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIVinfected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005; 21(9): 757-67.
152. Calza L, Manfredi R, Chiodo F. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 2002; 30(1): 26-31.
153. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.
154. Gerber JG, Kitch DW, Fichtenbaum CJ, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 2008; 47(4): 459-66.
155. Negredo E, Molto J, Puig J, et al. Ezetimibe, a promising lipidlowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 2006; 20(17): 2159-64.
156. Wohl D, Hsue P, Richard S, et al. Ezetimibe's Effects on the LDL Cholesterol Levels of HIV-infected Patients Receiving HAART 14th Conference on Retroviruses and Opportunistic Infections 2007; Abstract 39.
157. Fessel WJ, Follansbee SE, Rego J. High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution. AIDS 2002; 16(13): 1785-9.
158. Calabrese LH, Albrecht M, Young J, et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med 2003; 348(23): 2323-8.
159. Jahangiri B, Haddad H. Cardiac transplantation in HIV-positive patients: are we there yet? J Heart Lung Transplant 2007; 26(2): 103-7.
160. Bisleri G, Morgan JA, Deng MC, Mancini DM, Oz MC. Should HIV-positive recipients undergo heart transplantation? J Thorac Cardiovasc Surg 2003; 126(5): 1639-40.
161. Morgan JA, Bisleri G, Mancini DM. Cardiac transplantation in an HIV-1-infected patient. N Engl J Med 2003; 349(14): 1388-9; author reply -9.
162. Gupta S, Markham DW, Mammen PP, et al. Long-term follow-up of a heart transplant recipient with documented seroconversion to HIV-positive status 1 year after transplant. Am J Transplant 2008 Feb 19.
163. Roland ME, Adey D, Carlson LL, Terrault NA. Kidney and liver transplantation in HIV-infected patients: case presentations and review. AIDS Patient Care STDS 2003; 17(10): 501-7.
164. Stock PG, Roland ME. Evolving clinical strategies for transplantation in the HIV-positive recipient. Transplantation 2007; 84(5): 563-71.
165. Boccara F, Teiger E, Cohen A, et al. Percutaneous coronary intervention in HIV infected patients: immediate results and long term prognosis. Heart 2006; 92(4): 543-4.
166. Segev A, Cantor WJ, Strauss BH. Outcome of percutaneous coronary intervention in HIV-infected patients. Catheter Cardiovasc Interv 2006; 68(6): 879-81.
167. Matetzky S, Domingo M, Kar S, et al. Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 2003; 163(4): 457-60.
168. Stollberger C, Armbruster C, Gmeinhart B, Finsterer J. Thrombosis of a drug-eluting stent after almost 2 years in an HIV-infected patient. AIDS 2007; 21(8): 1064-6.
169. Boccara F, Cohen A, Di Angelantonio E, et al. Coronary artery bypass graft in HIV-infected patients: a multicenter case control study. Curr HIV Res 2008; 6(1): 59-64.
170. Trachiotis GD, Alexander EP, Benator D, Gharagozloo F. Cardiac surgery in patients infected with the human immunodeficiency virus. Ann Thorac Surg 2003; 76(4): 1114-8; discussion 8.